Oct. 22, 2008 - Phase 3 sleep-lab study demonstrated that low dose sublingual Intermezzo®, used at the time of a middle of the night awakening, significantly shortened time to return to sleep vs. placebo - Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced that a Phase 3 study evaluating the safety and efficacy of its lead product candidate, Intermezzo® (zolpidem tartrate sublingual lozenge), has been published in the September 2008 issue of SLEEP, a publication of the Associated Professional Sleep Societies. Intermezzo® is a low dose, buffered, sublingual formulation of zolpidem intended to be the first prescription sleep aid to be indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep... Transcept Pharmaceuticals' Press Release -
Thursday, October 23, 2008
Transcept Pharmaceuticals : Clinical Study of Intermezzo® for the Treatment of Middle-of-the-Night Awakening Published in SLEEP
Oct. 22, 2008 - Phase 3 sleep-lab study demonstrated that low dose sublingual Intermezzo®, used at the time of a middle of the night awakening, significantly shortened time to return to sleep vs. placebo - Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced that a Phase 3 study evaluating the safety and efficacy of its lead product candidate, Intermezzo® (zolpidem tartrate sublingual lozenge), has been published in the September 2008 issue of SLEEP, a publication of the Associated Professional Sleep Societies. Intermezzo® is a low dose, buffered, sublingual formulation of zolpidem intended to be the first prescription sleep aid to be indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep... Transcept Pharmaceuticals' Press Release -
